Literature DB >> 18506774

Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines.

Ryan J Bourgo1, Wesley A Braden, Susanne I Wells, Erik S Knudsen.   

Abstract

High-risk human papilloma virus (HPV) encodes two oncoproteins, E6 and E7, which are vital to viral replication and contribute to the development of cervical cancer. HPV16 E7 can target over 20 cellular proteins, but is best known for inactivating the retinoblastoma (RB) tumor suppressor. RB functions by restraining cells from entering S-phase of the cell cycle, thus preventing aberrant proliferation. While it is well established that HPV16 E7 facilitates the degradation of the RB protein, the ability of the RB pathway to overcome E7 action is less well understood. In this study the RB-pathway was activated via the overexpression of the p16ink4a tumor suppressor or ectopic expression of an active allele of RB (PSM-RB). While p16ink4a had no influence on cell cycle progression, PSM-RB expression was sufficient to induce a cell cycle arrest in both SiHa and HeLa cells, HPV positive cervical cancer cell lines. Strikingly, this arrest led to the downregulation of E2F target gene expression, which was antagonized via enhanced HPV-E7 expression. Since downmodulation of E7 function is associated with chronic growth arrest and senescence, the effect of PSM-RB on proliferation and survival was evaluated. Surprisingly, sustained PSM-RB expression impeded the proliferation of SiHa cells, resulting in both cell cycle inhibition and cell death. From these studies we conclude that active RB expression can sensitize specific cervical cancer cells to cell cycle inhibition and cell death. Thus, targeted therapies involving activation of RB function may be effective in inducing cell death in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18506774      PMCID: PMC2978426          DOI: 10.1002/mc.20456

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

1.  Active RB elicits late G1/S inhibition.

Authors:  Steven P Angus; Anne F Fribourg; Michael P Markey; Sarah L Williams; Henning F Horn; James DeGregori; Timothy F Kowalik; Kenji Fukasawa; Erik S Knudsen
Journal:  Exp Cell Res       Date:  2002-06-10       Impact factor: 3.905

Review 2.  Emerging roles for E2F: beyond the G1/S transition and DNA replication.

Authors:  Hugh Cam; Brian David Dynlacht
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

Review 3.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

4.  Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.

Authors:  S J Lee; Y S Cho; M C Cho; J H Shim; K A Lee; K K Ko; Y K Choe; S N Park; T Hoshino; S Kim; C A Dinarello; D Y Yoon
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

Review 5.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

Review 6.  The Rb/E2F pathway and cancer.

Authors:  J R Nevins
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

7.  The viral oncogene human papillomavirus E7 deregulates transcriptional silencing by Brm-related gene 1 via molecular interactions.

Authors:  Daeyoup Lee; Chunghun Lim; Taegun Seo; Hyockman Kwon; Hyesun Min; Joonho Choe
Journal:  J Biol Chem       Date:  2002-10-07       Impact factor: 5.157

Review 8.  Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.

Authors:  Anna-Marija Helt; Denise A Galloway
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

9.  The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle.

Authors:  E R Flores; B L Allen-Hoffmann; D Lee; P F Lambert
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.

Authors:  Ni Sima; Wei Wang; Debo Kong; Dongrui Deng; Qian Xu; Jianfeng Zhou; Gang Xu; Li Meng; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  Apoptosis       Date:  2008-02       Impact factor: 4.677

View more
  4 in total

Review 1.  Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer.

Authors:  Momeneh Ghanaat; Nasser Hashemi Goradel; Arash Arashkia; Nasim Ebrahimi; Sajjad Ghorghanlu; Ziba Veisi Malekshahi; Esmail Fattahi; Babak Negahdari; Hami Kaboosi
Journal:  Acta Pharmacol Sin       Date:  2021-02-25       Impact factor: 6.150

Review 2.  Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.

Authors:  T Lampejo; D Kavanagh; J Clark; R Goldin; M Osborn; P Ziprin; S Cleator
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

3.  An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein.

Authors:  Clare Nicol; Özlem Cesur; Sophie Forrest; Tamara A Belyaeva; David H J Bunka; G Eric Blair; Nicola J Stonehouse
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

4.  Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells.

Authors:  Sai-Fung Chung; Chi-Fai Kim; Ho-Yin Chow; Hiu-Chi Chong; Suet-Ying Tam; Yun-Chung Leung; Wai-Hung Lo
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.